Title: Primary cardiac synovial sarcoma that was continuous with the mitral valve caused severe thrombocytopenia: a case report

Reviewer's report:

There are about sixty cases described in 54 articles until now (Coli et al. Journal of Cardiothoracic Surgery 2018; 13:84). However in PubMed there are about 102 articles with primary cardiac synovial sarcoma; none of these was associated with thrombocytopenia. Molecular demonstration of SYT-SS1 or SYT-SSX2 fusion transcript is essential in confirming the diagnosis. Complete surgical resection of cardiac synovial sarcoma is as gold standard of therapy is rarely possible because of the infiltrativeness and extension of the neoplasm. Although guidelines for the treatment are not well established, due to limited number of cases reported, chemotherapy and radiotherapy are frequently administered and seem to prolong mean patient's survival. Heart transplantation for lower grade and less aggressive cardiac sarcomas could be a treatment solution with better outcome.

Severe thrombocytopenia associated with cardiac synovial sarcoma is a strong point of this case report. Were there other iatrogenic causes of thrombocytopenia like heparin, antiplatelet drugs (due to the recently stroke diagnosing) or alcohol excluded? What about spleen of this patient?

Why the patient did not make chemotherapy or radiotherapy after surgery? Was this case discussed by the heart team?

In the literature there is other cases reported with thrombocytopenia associated with cardiac tumors. (Fatal thrombocytopenia associated with intracardiac mass. J Cardiovasc Dis Res. 2012 Apr-Jun; 3(2): 65-66). It is therefore important to underline that probably there are some cases underdiagnosed.

The English language need improvement (for example: "when the tumor is cut open", instead of "when the tumor was cut opened".

Level of interest
Please indicate how interesting you found the manuscript:

An article of importance in its field
Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal.